💼 JSR’s Protein A chromatography technology will support faster and more efficient therapy production.
🌍 The acquisition emphasizes MilliporeSigma’s commitment to innovation in pharmaceuticals. It will close by Q2 2026.
Introduction:
This article discusses MilliporeSigma’s decision to acquire the chromatography business of JSR Life Sciences, marking a strategic move to enhance their bioprocessing offerings, particularly in the production of monoclonal antibodies. The acquisition aims to bolster MilliporeSigma’s position in the bioprocessing market through an expanded portfolio of chromatography solutions.
- MilliporeSigma, part of Merck KGaA, has signed an agreement to acquire JSR Life Sciences’ chromatography business.
- The acquisition will strengthen MilliporeSigma’s downstream processing portfolio with advanced Protein A chromatography capabilities.
- This move is expected to improve the efficiency and scalability of biopharmaceutical therapy production, particularly for monoclonal antibodies.
- The chromatography business of JSR Life Sciences, based in Belgium, is known for its Protein A resins, which are crucial for purifying monoclonal antibodies.
- The transaction is projected to close by the end of the second quarter of 2026, reinforcing MilliporeSigma’s commitment to long-term investments in antibody production technologies.
Conclusion:
The acquisition of JSR Life Sciences’ chromatography business represents a significant advancement for MilliporeSigma in the bioprocessing sector. By integrating JSR’s expertise, MilliporeSigma aims to enhance the production processes of biopharmaceuticals and facilitate faster market entry for antibody therapies. This strategic investment underscores the increasing importance of efficient bioprocessing technologies within the pharmaceutical industry.
